{“timestamp”:1540561641907,”status”:412,”error”:”Precondition Failed”,”exception”:”org.springframework.web.method.annotation.MethodArgumentTypeMismatchException”,”message”:”For input string: “content””,”path”:”/company/financial-report/content”}
Article source: http://www.otcmarkets.com/financialReportViewer?symbol=HQDA&id=205032
{“timestamp”:1540561641907,”status”:412,”error”:”Precondition Failed”,”exception”:”org.springframework.web.method.annotation.MethodArgumentTypeMismatchException”,”message”:”For input string: “content””,”path”:”/company/financial-report/content”}
Article source: http://www.otcmarkets.com/financialReportViewer?symbol=HQDA&id=205032
{“timestamp”:1540540080588,”status”:412,”error”:”Precondition Failed”,”exception”:”org.springframework.web.method.annotation.MethodArgumentTypeMismatchException”,”message”:”For input string: “content””,”path”:”/company/financial-report/content”}
Article source: http://www.otcmarkets.com/financialReportViewer?symbol=IMPZY&id=205033
{“timestamp”:1540518387168,”status”:412,”error”:”Precondition Failed”,”exception”:”org.springframework.web.method.annotation.MethodArgumentTypeMismatchException”,”message”:”For input string: “content””,”path”:”/company/financial-report/content”}
Article source: http://www.otcmarkets.com/financialReportViewer?symbol=ALRS&id=204919
{“timestamp”:1540496785105,”status”:412,”error”:”Precondition Failed”,”exception”:”org.springframework.web.method.annotation.MethodArgumentTypeMismatchException”,”message”:”For input string: “content””,”path”:”/company/financial-report/content”}
Article source: http://www.otcmarkets.com/financialReportViewer?symbol=DYNE&id=204874
This application has no explicit mapping for /error, so you are seeing this as a fallback.
Article source: http://www.otcmarkets.com/financialReportViewer?symbol=GNCP&id=196542
Part of Larger Corporate Partnering Effort During the J.P. Morgan 36th Annual Healthcare Conference
ATLANTA, GA, Jan. 02, 2018 (GLOBE NEWSWIRE) — GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines and immunotherapies, announced today that its Chief Scientific Officer, Farshad Guirakhoo, PhD, will deliver a presentation at the China Showcase during the Biotech Showcase 2018 conference. Dr. Guirakhoo’s presentation will be made at 2:00 p.m. on January 7, 2018 at the Parc 55 hotel in San Francisco, California.
The China Showcase is an event for companies and investors interested in cross-border investment and strategic partnering opportunities. Dr. Guirakhoo’s presentation will focus on the broad utility and impressive dataset being developed for GeoVax’s MVA-VLP vaccine platform, and he will provide an overview of the Company’s vaccine development programs in the areas of HIV, Zika, Lassa fever, malaria, hepatitis B immunotherapy, and immuno-oncology. Following the presentation, senior management of GeoVax will be available for one-on-one meetings with investment professionals and business development representatives from the life sciences industry.
Robert McNally, PhD, GeoVax’s President CEO, commented, “While our presentation and attendance at the China Showcase is primarily focused on strategic opportunities with Chinese investors and biopharmaceutical companies, this is part of our larger effort during multiple events in San Francisco connected to the J.P. Morgan Annual Healthcare Conference on January 8-11, 2018. We continue to build a strong pipeline of preventive vaccines and immuno-therapeutics addressing multiple unmet medical needs in infectious diseases and cancer. We look forward to connecting with many potential collaborators, partners and investors to communicate the value of our technology and the rationale for investing in the advancement of our vaccines to human clinical trials.”
Interested parties may schedule meetings with GeoVax through the conference websites for the Biotech Showcase (https://ebdgroup.knect365.com/biotech-showcase/), the Redefining Early Stage Investments (RESI) Conference (http://www.resiconference.com/), or through the partnering system hosted by the Biotechnology Innovation Organization (http://convention.bio.org/partner/). Meetings may also be scheduled by contacting Company management directly.
About GeoVax
GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platforms. The Company’s HIV vaccine for the clade B epidemic in the Americas, Australia, Japan and Europe is advancing in human trials conducted by the HIV Vaccine Trials Network (HVTN). Preclinical programs are focused on preventive vaccines for Zika virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines for HIV, chronic hepatitis B infections and cancers. GeoVax’s vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine, mimicking a natural infection and effectively stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.geovax.com.
Robert T. McNally, Ph.D. GeoVax Labs, Inc. investor@geovax.com 678-384-7220
Article source: http://www.otcmarkets.com/stock/GOVX/news?id=179327
BERLIN, GERMANY–(Marketwired – Jan 2, 2018) –
Note to editors: To view the photo associated with this press release, please visit the following link: The BOMBARDIER ALP-45 Dual-Power Locomotive (Photo:Roman Porta)
Rail technology leader Bombardier Transportation announced today that New Jersey Transit Corporation (NJ TRANSIT) has exercised an option for 17 additional BOMBARDIER ALP-45 dual-power locomotives. This second call off is valued at approximately $160 million US (133 million euro) and is based on a contract for 26 locomotives signed in 2008. NJ TRANSIT exercised a first option for nine units in 2011 and the contract includes options for up to 37 more units.
“This option order is confirmation of the confidence NJ TRANSIT has in our highly innovative, energy efficient, reliable, and safe equipment,” said Benoit Brossoit, President, Americas Region, Bombardier Transportation. “The new locomotives will comply with the EPA’s Tier 4 Exhaust Limits, making them environmentally friendly which is especially important in a metropolitan area like New York.”
The dual-power locomotives are capable of operating under both diesel power and alternating current electric power from overhead sources. Their flexible power system enables the locomotives to operate across the entire NJ TRANSIT rail system, which includes both electrified and non-electrified lines, thus allowing passengers to ride a single train between New Jersey and New York Penn Station without having to change trains. Their introduction in 2011-2012 at NJ TRANSIT and the then Agence Métropolitaine de Transport in Montreal (now named Réseau de transport métropolitain) marked a first for this technology in North America.
The locomotives will be manufactured at Bombardier sites in Germany and Poland. Delivery is scheduled to start in November 2019.
NJ TRANSIT is the largest statewide public transportation system in the United States and an established customer of Bombardier. Over the years, Bombardier has provided 100 electric and dual-power locomotives, hundreds of push-pull commuter coaches, and 429 Multilevel vehicles to NJ TRANSIT. In addition, Bombardier was a member of the consortium that designed and built NJ TRANSIT’s turnkey RiverLINE light rail system between Camden and Trenton, New Jersey and now operates and maintains the system under a contract with NJ TRANSIT.
About New Jersey Transit
NJ TRANSIT is the nation’s largest statewide public transportation system providing more than 944,000 weekday trips on 252 bus routes, three light rail lines, 12 commuter rail lines and through Access Link paratransit service. It is the third largest transit system in the country with 166 rail stations, 62 light rail stations and more than 19,000 bus stops linking major points in New Jersey, New York and Philadelphia.
About Bombardier Transportation
Bombardier Transportation is a global leader in rail technology and offers the broadest portfolio in the industry. It covers the full spectrum of rail solutions, ranging from trains to sub-systems and signalling. The company also provides complete transport systems, e-mobility technology and maintenance services. As an innovation driver, Bombardier Transportation continuously breaks new ground in sustainable mobility. It provides integrated solutions that create substantial benefits for operators, passengers and the environment. Headquartered in Berlin, Germany, Bombardier Transportation employs around 37,150 people and its products and services operate in over 60 countries.
About Bombardier
Bombardier is the world’s leading manufacturer of both planes and trains. Looking far ahead while delivering today, Bombardier is evolving mobility worldwide by answering the call for more efficient, sustainable and enjoyable transportation everywhere. Our vehicles, services and, most of all, our employees are what make us a global leader in transportation.
Bombardier is headquartered in Montréal, Canada and our shares are traded on the Toronto Stock Exchange (BBD). In the fiscal year ended December 31, 2016, we posted revenues of $16.3 billion. News and information are available at bombardier.com or follow us on Twitter @Bombardier.
Notes to Editors
To receive our press releases, please visit the RSS Feed section.
Bombardier and ALP are trademarks of Bombardier Inc. or its subsidiaries.
You can also contact one of our worldwide contacts for specific press inquiries.
Article source: http://www.otcmarkets.com/stock/BDRBF/news?id=179252
BERLIN, GERMANY–(Marketwired – Jan 2, 2018) –
Note to editors: To view the photo associated with this press release, please visit the following link: The BOMBARDIER ALP-45 Dual-Power Locomotive (Photo:Roman Porta)
Rail technology leader Bombardier Transportation announced today that New Jersey Transit Corporation (NJ TRANSIT) has exercised an option for 17 additional BOMBARDIER ALP-45 dual-power locomotives. This second call off is valued at approximately $160 million US (133 million euro) and is based on a contract for 26 locomotives signed in 2008. NJ TRANSIT exercised a first option for nine units in 2011 and the contract includes options for up to 37 more units.
“This option order is confirmation of the confidence NJ TRANSIT has in our highly innovative, energy efficient, reliable, and safe equipment,” said Benoit Brossoit, President, Americas Region, Bombardier Transportation. “The new locomotives will comply with the EPA’s Tier 4 Exhaust Limits, making them environmentally friendly which is especially important in a metropolitan area like New York.”
The dual-power locomotives are capable of operating under both diesel power and alternating current electric power from overhead sources. Their flexible power system enables the locomotives to operate across the entire NJ TRANSIT rail system, which includes both electrified and non-electrified lines, thus allowing passengers to ride a single train between New Jersey and New York Penn Station without having to change trains. Their introduction in 2011-2012 at NJ TRANSIT and the then Agence Métropolitaine de Transport in Montreal (now named Réseau de transport métropolitain) marked a first for this technology in North America.
The locomotives will be manufactured at Bombardier sites in Germany and Poland. Delivery is scheduled to start in November 2019.
NJ TRANSIT is the largest statewide public transportation system in the United States and an established customer of Bombardier. Over the years, Bombardier has provided 100 electric and dual-power locomotives, hundreds of push-pull commuter coaches, and 429 Multilevel vehicles to NJ TRANSIT. In addition, Bombardier was a member of the consortium that designed and built NJ TRANSIT’s turnkey RiverLINE light rail system between Camden and Trenton, New Jersey and now operates and maintains the system under a contract with NJ TRANSIT.
About New Jersey Transit
NJ TRANSIT is the nation’s largest statewide public transportation system providing more than 944,000 weekday trips on 252 bus routes, three light rail lines, 12 commuter rail lines and through Access Link paratransit service. It is the third largest transit system in the country with 166 rail stations, 62 light rail stations and more than 19,000 bus stops linking major points in New Jersey, New York and Philadelphia.
About Bombardier Transportation
Bombardier Transportation is a global leader in rail technology and offers the broadest portfolio in the industry. It covers the full spectrum of rail solutions, ranging from trains to sub-systems and signalling. The company also provides complete transport systems, e-mobility technology and maintenance services. As an innovation driver, Bombardier Transportation continuously breaks new ground in sustainable mobility. It provides integrated solutions that create substantial benefits for operators, passengers and the environment. Headquartered in Berlin, Germany, Bombardier Transportation employs around 37,150 people and its products and services operate in over 60 countries.
About Bombardier
Bombardier is the world’s leading manufacturer of both planes and trains. Looking far ahead while delivering today, Bombardier is evolving mobility worldwide by answering the call for more efficient, sustainable and enjoyable transportation everywhere. Our vehicles, services and, most of all, our employees are what make us a global leader in transportation.
Bombardier is headquartered in Montréal, Canada and our shares are traded on the Toronto Stock Exchange (BBD). In the fiscal year ended December 31, 2016, we posted revenues of $16.3 billion. News and information are available at bombardier.com or follow us on Twitter @Bombardier.
Notes to Editors
To receive our press releases, please visit the RSS Feed section.
Bombardier and ALP are trademarks of Bombardier Inc. or its subsidiaries.
You can also contact one of our worldwide contacts for specific press inquiries.
Article source: http://www.otcmarkets.com/stock/BDRBF/news?id=179252
CSE: MDM FSE: 2M0 OTCQB: MRPHF
KELOWNA, BC, Jan. 1, 2018 /CNW/ – Marapharm Ventures Inc. “Marapharm” announces achievements in 2017.
2017 was a year of incredible growth for Marapharm. The corporate head office moved to a new larger location to accommodate its rapidly expanding business activities in Nevada, California, and Washington.
Shareholders expressed confidence in Marapharm and its future by exercising 22,547,420 warrants from January 19, 2017 to September 6, 2017 for proceeds totaling $11,035,252.00.
Directors, consultants, and employees also expressed their confidence in Marapharm by exercising 1,200,000 of their stock options for proceeds of $600,000.00. In addition, Marapharm’s President purchased $500,00.00 of warrants and the directors purchased $300,000.00 of warrants totaling $800,000.00 worth of proceeds to Marapharm.
In May of 2017 the Company raised $1,748,480.00 through a USD Convertible Bond offering.
Marapharm provided a unique warrant offering investment opportunity to investors, a warrant offering, with a purchase price of $.010 per warrant, exercisable at $2.90 for a period of three years. There was significant interest in the offering, therefore Marapharm has been closing the offering in tranches. To date 31,219,650 warrants have been subscribed totaling $3,121.965.00. Marapharm has extended the offering to close the final tranche on January 31, 2018.
Market activity was strong in 2017 with increased trading volumes as follows:
FSE/Germany (2M0) traded 90,000,000 shares
OTC (MRPHF) traded 20,061,597 shares
CSE (MDM) traded 67,130,696 shares
Total volume for the 2017 trading year was 177,192,293 shares valued at approximately $200,000,000.00 Canadian.
Marapharm announced September 20, 2017 that it qualified and had been included in the CSE25 Index, a subgroup of the CSE Composite Index, comprised of the largest companies trading on the CSE.
Marapharm announced April 19, 2017 that it was added to the United States Marijuana Index, which tracks the leading cannabis stocks trading on North American stock exchanges. The Index is a measure of the value of a section of the stock market.
In August 2017, Marapharm was invited to apply to move its US trading from the OTCQB up to the OTCQX Best Markets. Final approval was granted on December 26th, 2017 and trading will commence on this premier platform January 2, 2018.
Nevada
On November 17, 2017, Marapharm was pleased to host an Open House event in Las Vegas at the Marapharm facility in which more than 300 attended to view the nearly-completed cultivation buildings. This gave shareholders and investors an opportunity to walk through the future cultivation centers and discuss with corporate directors the vision for Marapharm moving forward. A sod turning was performed at this event for the commencement of the next building, a 65,000 square foot, three story, cultivation and processing building.
Plans for this building were put out for bid in October of 2017, and Marapharm selected American Builders, located in Carson City, Nevada. Construction will begin immediately.
Cultivation began in two interim buildings with a focus on specific strains including; Kosher Kush, Grape God, Blueberry, Orient Express, Tangilope, Plum Crazy and Tangie. The focus will be to provide a premium quality organic product to the Nevada market.
One of the biggest accomplishments for the year, however, was the acquisition of 5 recreational marijuana licenses through the State Department of Taxation. These include 2 cultivation licenses, one production license, and 2 distribution licenses for a total of close to 300,000 square feet of licensing for recreational marijuana. Each one of these licenses now hold significant value in the current market.
Washington
Marapharm exercised the option to purchase 13.6 acres of land and buildings zoned for cannabis cultivation and production. Demolition of the building interior commenced and is now complete. Washington State imposed new energy guidelines during the year which required extensive insulation of the existing cultivation building. This is now complete and re-construction of the interior is scheduled for the new year. Cultivation in Washington will be directed by an award-winning cultivator and will focus on market specific strains.
California
During the year Marapharm bought and closed on two properties zoned for medical cannabis cultivation and production. These transactions provided the company with 4 medical marijuana licenses; 2 cultivation and 2 processing.
Subsequent to these purchases, Marapharm entered into an agreement to purchase a medical marijuana dispensary. The transaction is scheduled to complete in January, 2018.
The dispensary has received approval for a recreational marijuana dispensary license and is positioned to provide a venue for the taxable transactions required by California State law to apply for recreational licensing for all other licenses held by the Company in the State of California. On completion, this will allow the Company to hold 6 recreational licenses in California.
Canada
The Company continues to hold an application submitted to Health Canada for the purposes of cultivating and distributing medical marijuana. Additional information will be provided in regards to Marapharm’s staff profile, as well as details outlining the possibility of a new location.
There is a significant growth with the online presence evidenced by a 48% increase in visits to the www.marapharm.com site, as well as 544% new e-mail subscribers which now totals approximately 1500.
Marapharm.tv
Marapharm started its own online TV show which airs daily via www.marapharm.tv. The purpose is to educate the public as to what is happening in the industry from different perspectives such as business, personal, and political while addressing current issues facing the cannabis industry. The website was developed and commenced with daily web updates on April 27th, 2017, adding daily shows on November 21st, 2017. A market report has also been integrated into the site to highlight Marapharm’s progress and provide information to shareholders and potential investors. The site has a growing demographic of loyal followers.
Veritas Pharma Inc.
Marapharm holds a total of 6,100,000 common shares of Veritas (a public company trading on: CSE: VRT; OTC: VRTHF; FSE: 2VP) representing approximately 15% in the share capital of the issuer, and assuming the exercise of the company’s total 11,500,000 warrants, Marapharm would hold a total of 17,600,000 common shares or approximately 32% of the issued and outstanding common shares of the issuer, Veritas Pharma Inc. Marapharm invested in the company on January 9, 2017, January 11, 2017, and October 19, 2017.
The securities were acquired for investment and synergy purposes.
Other Business
Pursuant to the Company’s Restricted Stock Unit plan “RSU”, the shareholders and board voted to approve the issuance of 9,363,494 restricted stock units to directors, officers, consultants and staff for their contributions and vision which has enhanced Marapharm’s value for all shareholders and stakeholders. In addition, the board approved the issuance of 2,500,000 stock options from its fixed stock option plan to directors, officers, consultants and staff.
“We’ve more than met our goals for 2017 and we’ve set even higher ones for 2018. Our entire team is more than ready for the new year that we believe will be filled with achievement! Based on assumptions that cannabis prices remain as they are and that we build out all the footage allowed for by the licenses we own, the projections are almost half a billion dollars of annual revenue for Marapharm. That is a milestone to reach for! The cannabis industry is exiting!” Linda Sampson, CEO.
ABOUT MARAPHARM VENTURES INC.
www.marapharm.com
Marapharm is a publicly traded company primarily investing in the medical and recreational cannabis space, with corporate operations based in British Columbia, Canada. Since 2016 they have rapidly expanded their footprint to include production locations in the key North American states of Washington, Nevada, and California. They actively seek expansion opportunities worldwide.
SOCIAL MEDIA:
Facebook: facebook.com/marapharm
Twitter: twitter.com/marapharm
Web Program: marapharm.tv
STOCK EXCHANGES:
Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, and in Europe, ticker symbol 2Mo on the FSE. Marapharm also trades on other recognized platforms in Europe including Stuttgart, Tradegate, L S, Quotnx, Dusseldorf, Munich, and Berlin.
Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.
MARIJUANA INDUSTRY INVOLVEMENT:
Canadian listings (CSE) will remain in good standing as long as they provide the disclosure that is rightly required by regulators and complying with applicable licensing requirements and the regulatory framework enacted by the applicable state in which they operate.
Marapharm owns marijuana licenses in California and Nevada. Marijuana is legal in each state however marijuana remains illegal under US federal law and the approach to enforcement of US federal law against marijuana is subject to change.
Shareholders and investors need to be aware that adverse enforcement actions could affect their investments and that Marapharm’s ability to access private and public capital could be affected and or could not be available to support continuing operations.
Marapharm’s business is conducted in a manner consistent with state law and is in compliance with licensing requirements.
Copies of licenses are posted on Marapharm’s website. Marapharm has internal compliance procedures in place and has compliance focused attorneys engaged in jurisdictions to monitor changes in laws for compliance with US federal and state law on an ongoing basis. These law firms inform any necessary changes to our policies and procedures for compliance in Canada and the US.
FORWARD – LOOKING STATEMENTS:
Certain statements contained in this news release constitute forward looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, ‘may”, “will”, “project”, “should”, ‘believe”, and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.
SOURCE Marapharm Ventures Inc.
Article source: http://www.otcmarkets.com/stock/MRPHF/news?id=179241
